Demographic and Clinicopathologic Factors of Patients With Hepatocellular Carcinoma in a Safety Net Hospital

被引:2
作者
Luu, Sommer [1 ]
Hsu, Cary [1 ]
Silberfein, Eric J. [1 ]
机构
[1] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA
关键词
Hepatocellular carcinoma; Safety net hospital; LIVER-TRANSPLANTATION; UNITED-STATES; SURVEILLANCE; DISPARITIES; SURVIVAL; BARRIERS; RATES; CARE; RACE;
D O I
10.1016/j.jss.2020.06.046
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Safety net hospitals have historically cared for a disproportionate number of patients of low socioeconomic status, racial and ethnic minorities, and patients with cancer. These innate challenges make safety net hospitals important in understanding how to improve access to cancer care in order to fit the needs of vulnerable patients and ultimately improve their outcomes. The purpose of this study is to characterize the current state and treatment of hepatocellular carcinoma (HCC) at Ben Taub Hospital, a safety net hospital in Houston, Texas. Materials and methods: A retrospective chart review was performed to review the demographic characteristics, clinicopathologic data, treatment strategies, and outcomes of HCC patients at Ben Taub Hospital between January 2012 and December 2014. Results: Two-hundred twenty-six men and 78 women with a mean age of 58 y underwent evaluation. Most (87%) were either uninsured or covered by Medicaid. The majority (69%) of patients presented with advanced (stage 2 or more) disease, with 58% of patients presenting with multiple lesions. Of the 40% that presented with a solitary lesion, the average size was 4.97 cm. Transarterial chemoembolization was used in 37% of patients and sorafenib was given to 26% of patients. Five patients underwent successful transplant. One hundred seventeen (38%) patients died of their disease, 25 patients are alive with no evidence of disease, and 159 patients have been lost to follow-up. Conclusions: Most patients with HCC presented to this safety net hospital with advanced disease; however, multiple local and systemic treatments were offered. Screening programs to detect HCC at an earlier stage are essential for successful long-term outcomes in a resource-strapped hospital with limited access to liver transplantation. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:374 / 380
页数:7
相关论文
共 35 条
  • [1] Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)
    Abou-Alfa, Ghassan K.
    Niedzwieski, Donna
    Knox, Jennifer J.
    Kaubisch, Andreas
    Posey, James
    Tan, Benjamin R.
    Kavan, Petr
    Goel, Rakesh
    Lammers, Philip Edward
    Bekaii-Saab, Tanios S.
    Tam, Vincent Channing
    Rajdev, Lakshmi
    Kelley, Robin Kate
    Siegel, Abby B.
    Balletti, Jennifer
    Harding, James J.
    Howard, Lawrence Schwartz
    Goldberg, Richard M.
    Bertagnolli, Monica M.
    Venook, Alan P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Nonalcoholic fatty liver disease
    Brunt, Elizabeth M.
    Wong, Vincent W. -S.
    Nobili, Valerio
    Day, Christopher P.
    Sookoian, Silvia
    Maher, Jacquelyn J.
    Bugianesi, Elisabetta
    Sirlin, Claude B.
    Neuschwander-Tetri, BrentA.
    Rinella, Mary E.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2015, 1
  • [3] Race, Ethnicity, and Socioeconomic Status Influence the Survival of Patients With Hepatocellular Carcinoma in the United States
    Artinyan, Avo
    Mailey, Brian
    Sanchez-Luege, Nicelio
    Khalili, Joshua
    Sun, Can-Lan
    Bhatia, Smita
    Wagman, Lawrence D.
    Nissen, Nicholas
    Colquhoun, Steven D.
    Kim, Joseph
    [J]. CANCER, 2010, 116 (05) : 1367 - 1377
  • [4] Differences in Physician Referral Drive Disparities in Surgical Intervention for Hepatocellular Carcinoma A Retrospective Cohort Study
    Chidi, Alexis P.
    Bryce, Cindy L.
    Myaskovsky, Larissa
    Fine, Michael J.
    Geller, David A.
    Landsittel, Douglas P.
    Tsung, Allan
    [J]. ANNALS OF SURGERY, 2016, 263 (02) : 362 - 368
  • [5] Practice Patterns and Attitudes of Primary Care Providers and Barriers to Surveillance of Hepatocellular Carcinoma in Patients With Cirrhosis
    Dalton-Fitzgerald, Eimile
    Tiro, Jasmin
    Kandunoori, Pragathi
    Halm, Ethan A.
    Yopp, Adam
    Singal, Amit G.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (04) : 791 - +
  • [6] Use of Surveillance for Hepatocellular Carcinoma Among Patients With Cirrhosis in the United States
    Davila, Jessica A.
    Morgan, Robert O.
    Richardson, Peter A.
    Du, Xianglin L.
    McGlynn, Katherine A.
    El-Serag, Hashem B.
    [J]. HEPATOLOGY, 2010, 52 (01) : 132 - 141
  • [7] Optimizing cancer care for hepatocellular carcinoma at a safety-net hospital: The value of a multidisciplinary disease management team
    Duininck, Grace
    Lopez-Aguiar, Alexandra G.
    Lee, Rachel M.
    Miller, Lesley
    Dariushnia, Sean
    Wu, Christina
    Alese, Olatunji B.
    Lin, Jolinta Y.
    Wedd, Joel
    Adams, Andrew
    Maithel, Shishir K.
    Russell, Maria C.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2019, 120 (08) : 1365 - 1370
  • [8] Epidemiology of Hepatocellular Carcinoma in the United States: Where Are We? Where Do We Go?
    El-Serag, Hashem B.
    Kanwal, Fasiha
    [J]. HEPATOLOGY, 2014, 60 (05) : 1767 - 1775
  • [9] Liver disease in alpha 1-antitrypsin deficiency: A review
    Fairbanks, Kyrsten D.
    Tavill, Anthony S.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (08) : 2136 - 2141
  • [10] Patient-Reported Barriers Are Associated With Lower Hepatocellular Carcinoma Surveillance Rates in Patients With Cirrhosis
    Farvardin, Sherean
    Patel, Jaimin
    Khambaty, Maleka
    Yerokun, Olutola A.
    Mok, Huram
    Tiro, Jasmin A.
    Yopp, Adam C.
    Parikh, Neehar D.
    Marrero, Jorge A.
    Singal, Amit G.
    [J]. HEPATOLOGY, 2017, 65 (03) : 875 - 884